Geistlich unveils vallos – a new demineralised allograft that sets the pace for regeneration

Geistlich Pharma North America is setting the pace for expanded treatment options with the introduction of vallos, its first demineralised allograft. 

With two formulations for treatment flexibility, vallos granules are ideally suited for smaller routine defects while vallos f fibers are designed for larger more complex defects.

This Geistlich Select product line brings an added confidence to regenerative procedures, with:

  • Verified osteoinductive potential in every lot1
  • Consistent product quality1
  • Proven regenerative capacity by exhibiting all five elements of bone formation1
  • Vital bone after 18-20 weeks2

Geistlich Select: Geistlich is proud of the quality and safety of its products and consistently employs rigorous scientific validation and strict manufacturing processes. Extensive research and collaboration have created a partnership to bring you select allograft materials designed for clinical versatility and success. Demineralised vallos and vallos f offer clinicians more options to enhance their ability to manage a variety of clinical indications and are the first products to become part of the Geistlich Select family.

“We are excited to bring these first allograft innovations to clinicians, which provides them with new options for their regenerative procedures. We will be expanding our allograft product line with additional solutions in the near future, as part of our Geistlich Select family,” said Les Burrows, general manager of Geistlich Pharma North America.

1Data on file, DCI Donor Services Tissue Bank

2Robert A Wood & Brian L Mealey: J Periodontol. 2012 Mar;83(3):329-36. (Clinical Study)